Gaston-Dreyfus Remi 4
4 · Bionik Laboratories Corp. · Filed Dec 13, 2021
Insider Transaction Report
Form 4
Gaston-Dreyfus Remi
Director
Transactions
- Exercise/Conversion
Stock Option (right to buy)
2021-07-15−115,759→ 0 totalExercise: $3.60From: 2020-07-26Exp: 2026-07-26→ Common Stock, par value $0.001 per share (115,759 underlying) - Exercise/Conversion
Stock Option (right to buy)
2021-07-15−5,000→ 0 totalExercise: $3.16Exp: 2026-05-31→ Common Stock, par value $0.001 per share (5,000 underlying) - Exercise/Conversion
Common Stock, par value $0.001 per share
2021-07-15+115,759→ 1,595,209 total(indirect: Shares held through RGD Investissements S.A.S. and Lombard International Assurance SA) - Exercise/Conversion
Common Stock, par value $0.001 per share
2021-07-15+5,000→ 1,600,209 total(indirect: Shares held through RGD Investissements S.A.S. and Lombard International Assurance SA)
Holdings
- 61,256
Common Stock, par value $0.001 per share
Footnotes (2)
- [F1]Payment of exercise price was satisfied through the satisfaction of an Issuer promissory note held by the Reporting Person.
- [F2]The options vested 1,666 on May 31, 2019, 1,666 on November 30, 2019 and 1,668 on May 31, 2020.